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Background: We recently reported that Parkinsonian and dementia phenotypes emerge between 7-12 months of
age in tau-/- mice on a Bl6/129sv mixed background. These observations were partially replicated by another group
using pure Bl6 background tau-/- mice, but notably they did not observe a cognitive phenotype. A third group
using Bl6 background tau-/- mice found cognitive impairment at 20-months of age.
Results: To reconcile the observations, here we considered the genetic, dietary and environmental variables in
both studies, and performed an extended set of behavioral studies on 12-month old tau+/+, tau+/-, and tau-/- mice
comparing Bl6/129sv to Bl6 backgrounds. We found that tau-/- in both backgrounds exhibited reduced tyrosine
hydroxylase-positive nigral neuron and impaired motor function in all assays used, which was ameliorated by oral
treatment with L-DOPA, and not confounded by changes in body weight. Tau-/- in the C57BL6/SV129 background
exhibited deficits in the Y-maze cognition task, but the mice on the Bl6 background did not.
Conclusions: These results validate our previous report on the neurodegenerative phenotypes of aged tau-/- mice,
and show that genetic background may impact the extent of cognitive impairment in these mice. Therefore
excessive lowering of tau should be avoided in therapeutic strategies for AD.
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Tau protein is involved in the pathogenesis of Alzheimer’s
disease (AD), Parkinson’s disease (PD) and other tauopa-
thies [1]. It is proposed that hyperphosphorylated tau
causes neurotoxicity by various mechanisms including tau
aggregation and microtubule disassembly [2]. The forma-
tion of tau aggregates may interfere with the normal func-
tion of tau, by withdrawing the protein from the cytosolic
soluble pool [3]. A decrease in soluble tau is observed in
affected tissue from AD, PD and other tauopathies [3-5].
Nevertheless, reducing tau protein level has been pro-
posed as a potential therapeutic strategy for AD and epi-
lepsy [6]. Therefore, understanding the normal function of
tau protein and the consequences of its reduction is
important.
Various functions of tau have been proposed [7], how-
ever only a few have been confirmed in tau knockout
models. One major proposed function of tau, microtubule* Correspondence: ashley.bush@florey.edu.au
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unless otherwise stated.stabilization, is likely to have some redundancy from other
microtubule-associated proteins such as MAP1B, since
tau-/- mice are viable and fertile [8,9]. Tau has also been
implicated in axonal transport, but loss of tau does not ap-
pear to impact on this cellular function [10-12]. However,
loss of tau protein significantly delays the maturation of
neurons, and affects the size of the cell body as well as the
extent of dendritic arborization in primary cell culture
[13,14]. Tau protein also participates in protein trafficking,
as loss of tau changes the distribution of several proteins,
including Fyn and APP [5,15]. Tau-/- mice display compro-
mised synaptic function, evidenced by impaired long-term
potentiation (LTP) at 6-months of age [16], and impaired
long-term depression (LTD) at 12-months of age [17] have
been reported.
Loss of tau function impacts on mouse behavior. 4-week
old tau-/- mice (generated by Harada et al. [8]) have been
reported to exhibit motor deficits and muscle weakness
[18], and at 3-6 months of age tau-/- mice (generated by
Dawson et al. [13], on a Bl6 background) showed deficits
in the open field and balance beam tests [19]. Recently,
Ahmed et al. [16] reported that tau-/- mice (generated byThis is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/4.0), which permits unrestricted use, distribution, and
iginal work is properly credited. The Creative Commons Public Domain
g/publicdomain/zero/1.0/) applies to the data made available in this article,
Figure 1 Body weight in 12-months old Bl6 background and
Bl6/129sv background mice. a) For Bl6 background mice: Two-way
ANOVA: genotype (p = 0.049), gender (p = 0.008) effects and interaction
(p = 0.038). b) For Bl6/129sv background mice: Two-way ANOVA: no
genotype (p = 0.342), gender (p = 0.402) effects, nor interaction
(p = 0.835). n is indicated in the column of each group. *p < 0.05,
**p < 0.01, versus age-matched wild type mice (Bonferroni post hoc
test). Data are means ± SEM.
Lei et al. Molecular Neurodegeneration 2014, 9:29 Page 2 of 12
http://www.molecularneurodegeneration.com/content/9/1/29Tucker et al. [20]) at 6-months of age showed impaired
contextual and cued fear conditioning [16]. We previously
reported that no significant neurological deficits were ob-
served in tau-/- mice on a Bl6/129sv mixed background
(also created by Dawson et al. [13]) prior to 7 months of
age, but that they subsequently expressed significant
motor and cognitive deficits by 12-months of age, which
were caused by toxic brain iron accumulation and associ-
ated disruption of dopaminergic pathways [5]. The motor
deficits were also observed by two independent groups
using the same strain on a Bl6 background at 12-months
of age [21,22], but the latter proposed that these deficits
might be caused by weight gain [22]. Both reports found
no cognitive deficits at this stage, but Ma et al. [21] re-
ported impaired Morris Water Maze performance in tau-/-
mice at 20-months of age [21].
Here, we attempt to explain these discrepant results. We
considered the environmental and genetic variants in both
studies, and performed an extended set of behavioral exper-
iments on 12-months old tau+/+, tau+/-, and tau-/- mice
comparing Bl6 background to Bl6/129sv background. We
conclude that the motor dysfunction observed by us and by
others is not dependent on mouse weight, environmental
or genetic background, however cognitive impairment is
dependent on genetic background.
Results
We found no difference in weight between tau+/+, tau+/-
and tau-/- mice, on the Bl6/129sv background (Figure 1).
The female, but not the male, tau-/- and tau+/-mice were
significantly (≈20%; p = 0.005) heavier than female wild type
mice on the Bl6 background (Figure 1), similar to the ob-
servation by Morris et al. [22]. Unlike the Bl6/129sv strain,
female wild type Bl6 mice at 12 months of age were signifi-
cantly lighter than male mice (p < 0.001, Figure 1), a differ-
ence that was abolished by tau ablation.
We tested the effects of Bl6 background compared to
Bl6/129sv background on the motor performance of the
tau-/- mice at 12 months of age. We found that the latency
to fall in the accelerated Rotarod test was significantly re-
duced in tau-/- mice in both of genetic backgrounds by the
same proportion (-50% for Bl6 background, p = 0.003; -43%
for Bl6/129sv background, p = 0.033, Figure 2a). There
was a trend for poorer Rotarod performance in the
tau+/- mice in both backgrounds (One-way ANOVA
with post hoc test for linear trend, for Bl6, p = 0.002;
for Bl6/129sv, p = 0.002).
It was previously reported that latency to fall inversely
correlates with mouse body weight, and thus the motor
deficits observed in tau-/- mice might be due to increased
weight of the mutant [22]. We found no association
of weight with latency to fall in either tau-/- mice on Bl6
background (r2 = 0.003, p = 0.871, Figure 2b), tau-/- mice
on Bl6/129sv background (r2 = 0.043, p = 0.589, Figure 2c),all Bl6 mice (r2 = 0.041, p = 0.321, Additional file 1:
Figure S1a), or all Bl6/129sv mice (r2 = 0.087, p = 0.114,
Additional file 1: Figure S1b). Therefore, the tau-/- mice
deficits we observed in the Rotarod test are independent
of genetic background or mouse body weight.
The Pole test is an established assay for mouse move-
ment dysfunction [23]. We previously reported that
tau-/- mice on a Bl6/129sv background took significantly
longer than age-matched wild-type mice to both turn
and complete the test [5], a deficit that was also identi-
fied by other investigators studying tau-/- mice on a Bl6
background [22]. To directly compare the impact of
genetic background, we repeated the study with both
knockout and heterozygote strains on both back-
grounds, compared to their parental wild-types. This
showed that the motor impairments (Time to turn,
Time to finish) in the tau-/- strains in the pole test were
significant and comparable in either genetic background
(Time to turn: for Bl6 background, +127%, p = 0.004; for
Bl6/129sv background, +97%, p < 0.001; Time to finish:
Figure 2 Complete tau reduction impairs the performance of mice in accelerated Rotarod test at 12 months of age. a) Tau-/- mice
significantly maintained less time on the rod. Two-way ANOVA: genotype effects (p = 0.0002) but no genetic background (p = 0.061) effects or
interaction (p = 0.519). * p < 0.05, *** p < 0.001, versus age-matched wild type mice (Bonferroni post hoc test). n is indicated in the column of each
group. Gender distribution is given in Additional file 6: Table S1. Data are means ± SEM. b-c) No correlation between weight and Rotarod performance
in 12-month-old mice (n = 9 – 11). b) Between tau−/− mice in Bl6 background and weight (r2 = 0.003, p = 0.871 by Pearson’s regression). c) Between
tau−/− mice in Bl6/129sv background and weight (r2 = 0.043, p = 0.589 by Pearson’s regression).
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ground, +33%, p = 0.034; Figure 3). The heterozygotes did
not express significant deficits but there was a trend to in-
crease in the time to finish parameter compared to
background-matched controls (One-way ANOVA with
post hoc test for linear trend, for Bl6, p = 0.017; for Bl6/
129sv, p = 0.019). There was no correlation between the
mouse body weight and time to turn in the Pole test, simi-
lar to the results published by Morris et al. [22] (For all
Bl6 mice, r2 = 0.087, p = 0.135; For all Bl6/129sv mice,
r2 = 0.015, p = 0.569; Additional file 2: Figure S2).
We re-assessed tau-/- mice in the Open Field test (the
temporal profile data at 5 minute intervals are shown in
Additional file 3: Figure S3). Consistent with our previ-
ous results [5], we found a significant reduction in the
average distance per movement, in both genetic back-
grounds (Bl6, -14%, p = 0.005; Bl6/129sv, -17%, p =
0.014, Figure 4a). The velocity of the tau-/- mice was not
affected (Figure 4b), consistent with an increased timeFigure 3 Complete tau reduction impairs the performance of mice in
longer time to turn on the pole. Two-way ANOVA: genotype effects (p < 0.
(p = 0.352). b) Tau-/- mice took significantly longer time to descend the pol
background (p = 0.377) effects or interaction (p = 0.903). * p < 0.05, ** p < 0.
hoc test). n is indicated in the column of each group. Gender distribution iin movement (Bl6, +75%, p < 0.001; Bl6/129sv, +81%,
p = 0.031, Figure 4c), and increased distance of locomo-
tion (Bl6, +67%, p < 0.001; Bl6/129sv, +43%, p = 0.221,
Figure 4d). Analysis of the movement of the mice in the
first 10 mins revealed similar results to analysis of the
full 60 mins (Additional file 4: Figure S4).
The hindlimb clasping severity score has been used to
characterize mouse models of Parkinson’s disease and
other basal ganglia disorders [24-26]. We found a signifi-
cant difference between both strains of tau-/- mice and
their background controls, where tau-/- mice were more
prone to clasp (Bl6, +114%, p = 0.008; Bl6/129sv, +109%,
p < 0.001, Figure 5). Tau+/- mice did not express signifi-
cantly greater clasping but there was a trend compared
to wild type mice (One-way ANOVA with post hoc test
for linear trend, for Bl6, p = 0.004; for Bl6/129sv,
p = 0.001).
Automated gait analysis using the DigiGait treadmill
apparatus revealed clear alterations in the runningPole test at 12 months of age. a) Tau-/- mice took significantly
0001) but no genetic background (p = 0.255) effects or interaction
e. Two-way ANOVA: genotype effects (p = 0.001) but no genetic
01, *** p < 0.001, versus age-matched wild type mice (Bonferroni post
s given in Additional file 6: Table S1. Data are means ± SEM.
Figure 4 Complete tau reduction impairs the performance of mice in Openfield test at 12 months of age. a) Tau-/- mice averagely moved
significantly less distance per movement. Two-way ANOVA: genotype (p = 0.0002) and genetic background (p < 0.0001) effects but no interaction
(p = 0.725). b) Velocity. Two-way ANOVA: genetic background effects (p = 0.0003), but no genotype effects (p = 0.651) or interaction (p = 0.082).
c) Time of movement. Two-way ANOVA: genotype (p < 0.0001) and genetic background (p < 0.0001) effects, but no interaction (p = 0.121).
d) Distance of locomotion. Two-way ANOVA: genotype (p < 0.0001) and genetic background (p < 0.0001) effects, but no interaction (p = 0.064).
*p < 0.05, ** p < 0.01, *** p < 0.001, versus age-matched wild type mice (Bonferroni post hoc test). n is indicated in the column of each group.
Gender distribution is given in Additional file 6: Table S1. Data are means ± SEM.
Figure 5 Altered hindlimb clasping behavior in tau-/- mice at 12 months of age. a-b) Example of lack of hindlimb clasping (hindlimbs
splayed outwards away from abdomen, Scored 0, a; and hindlimb clasping behavior towards the abdomen, Scored 3, b). c) Tau-/- mice exhibited
significantly increased hindlimb clasp severity compared to its background control. Two-way ANOVA: genotype effects (p < 0.0001) but no genetic
background (p = 0.115) effects or interaction (p = 0.556). **p < 0.01, ***p < 0.001, versus age-matched wild type mice (Bonferroni post hoc test).
n is indicated in the column of each group. Gender distribution is given in Additional file 6: Table S1. Data are means ± SEM.
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(Figure 6, Additional file 5: Figure S5). This test was previ-
ously used to characterize 6-OHDA-intoxicated, MPTP-
intoxicated, and transgenic PD models [27-29]. The
dimensions of the strides (length and width) were not sig-
nificantly different (Additional file 5: Figure S5a), consist-
ent with their unchanged weight (Figure 1). At a speed of
15 cm/s, we found that tau+/- and tau-/- mice with Bl6/
129sv background showed significantly reduced stride
frequency for both forelimbs (-12%, p = 0.014 for tau+/-,
and -10%, p = 0.047 for tau-/-) and hindlimbs (-10%,
p = 0.026 for tau+/-, and -10%, p = 0.040 for tau-/-, Figure 6b),
compared to wild type mice. These tau-/- mice also showed
significantly reduced consistency of their running pattern
(-11%, p = 0.033, Figure 6c). Tau-/- mice on either back-
ground showed a significantly reduced ratio between stride
length and stance width in their hindlimbs (Bl6, -11%,
p = 0.049; Bl6/129sv, -17%, p = 0.014, Figure 6d), without a
major difference in their stride length (Figure 6e-f ).
Tau-/- mice on the Bl6/129sv background, but not on the
Bl6 background, showed reduced stance width (-13%,
p = 0.017) with increased variance (+5%, p = 0.037,
Figure 6f ), indicating impaired base of support, which
is consistent with the results from Rotarod test.
Tau-/- mice on either background also showed signifi-
cantly altered paw and/or step angles during movement
(Figure 6g-h), which are also indications of dysfunctional
ataxia [30]. Analysis of other gait dynamics also revealedFigure 6 Altered movement pattern of tau-/- mice at 12 months of ag
Digigait apparatus. b-h) parameters from Digigait analysis: stride frequency
100% alternate (c), stride length normalized to stance width (d), stride leng
background (e), stride length, stance width, and variability of hindlimb strid
mice in Bl6 background (g), and paw angle and step angle of mice in Bl6
file 5: Figure S5. One-way ANOVA were performed to determine the differe
*p < 0.05, **p < 0.01, ***p < 0.001. n is indicated in the column of each grou
means ± SEM.differences between genotypes, for example, tau-/- mice in
both backgrounds showed significant differences com-
pared to wild-type mice for swing, brake, propulsion and
stance durations of forelimbs (Additional file 5: Figure S5).
We showed previously that L-DOPA gavage rescued
the motor dysfunction observed in tau-/- mice [5], at
variance with the findings of Morris et al. [22]. Those
authors reported that the motor deficits on the Pole Test
observed in tau-/- mice on a Bl6 background were not
rescued by single I.P. or chronic L-DOPA therapy, com-
pared to sham-treated controls [22]. We believed it im-
portant to note, though, that the results of Morris et al.
[22] show that the tau-/- mice on a Bl6 background
expressed a significant impairment in the Pole Test be-
fore the L-DOPA treatment, which was abolished after
the treatment, indicating that the treatment might have
indeed partially rescued the phenotype. Therefore, we
repeated the experiment on tau-/- mice of both genetic
backgrounds, and found, in our hands, that L-DOPA
rescued the Pole test and Rotarod disability in both
strains. This independent cohort of 12-months old tau-/-
mice (in both genetic backgrounds) showed once again
significantly increased time to turn in Pole Test (+95%,
Bl6, p < 0.001; +64%, Bl6/129sv, p = 0.009, Figure 7a-b),
and significantly decreased latency to fall in the Rotarod
test (-58%, Bl6, p = 0.005; -59%, Bl6/129sv, p = 0.049,
Figure 7c-d). A single oral dose of L-DOPA completely
corrected the motor behaviors to similar levels as theire in Digigait analysis. a) Examples of footprint recorded by the
(b), percentage alternate gait where perfectly antiphase stepping is
th, stance width, and variability of hindlimb stride of mice in Bl6
e of mice in Bl6/129sv background (f), paw angle and step angle of
background (h). Additional gait analysis can be found in Additional
nces versus age-matched wild type mice for each individual parameter.
p. Gender distribution is given in Additional file 6: Table S1. Data are
Figure 7 Motor deficits are related to nigral degeneration. a-d) Single dose of L-DOPA (10 mg/kg, gavage) rescued motor impairment in
12-month-old tau-/- mice. a) Pole test for Bl6 background mice (time to turn). Two-way ANOVA: genotype effects (p = 0.0001) and interaction
(p = 0.008), but no treatment effects (p = 0.142). b) Pole test for Bl6/129sv background mice (time to turn). Two-way ANOVA: genotype (p = 0.032)
and treatment (p = 0.002) effects, with interaction (p = 0.009). c) Rotarod test for Bl6 background mice (latency to fall). Two-way ANOVA: genotype
effects (p = 0.009) and interaction (p = 0.041), but no treatment effects (p = 0.398). d) Rotarod test for Bl6/129sv background mice (latency to fall).
Two-way ANOVA: genotype effects (p = 0.032) and interaction (p = 0.047), but no treatment effects (p = 0.698). *p < 0.05, **p < 0.01, ***p < 0.001,
versus age-matched wild type mice (Bonferroni post hoc test). # < 0.05, ## p < 0.01, versus sham-treated tau-/- mice (Bonferroni post hoc test).
e) 12-month-old tau-/- mice showed reduced TH-positive nigral neuron number. Two-way ANOVA: genotype effects (p = 0.001), but no genetic
background (p = 0.729) effects or interaction (p = 0.799). * p < 0.05, **p < 0.01, versus age-matched wild type mice (Bonferroni post hoc test).
n is indicated in the column of each group. Gender distribution is given in Additional file 6: Table S1. Data are means ± SEM.
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test, -42%, Bl6, p = 0.033; -90%, Bl6/129sv, p = 0.001;
Rotarod, +111%, Bl6, p = 0.049; +190%, Bl6/129sv, p =
0.044, compared to sham-treated tau-/- mice), indicatingthat the behavioral abnormality observed in tau-/- mice
involves dysfunction of dopamine-related pathways,
consistent with nigral neurodegeneration we previously
described [5].
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we stereologically counted the tyrosine hydroxylase-positive
neurons in the substantia nigra pars compacta. Consistent
with the motor dysfunction, loss of tau protein induced ni-
gral neuron loss independent of genetic background (-30%,
Bl6, p = 0.0181; -36%, Bl6/129sv, p = 0.007, Figure 7e). This
is consistent with our previous report [5]. Tau+/- mice in
both backgrounds exhibited a trend to nigral neuron loss
(One-way ANOVA with post hoc test for linear trend; Bl6
p = 0.0172; Bl6/129sv p = 0.009, Figure 7e).
We interrogated the cognitive function of 12-month
old tau-/- mice using the Y-maze test. Consistent with
our previous observation [5], tau ablation in the Bl6/
129sv background caused a significantly decreased time
spent in the novel arm compared to wild-type controls
(p = 0.042, Figure 8a), indicating a spatial memory def-
icit. Tau+/- mice in the Bl6/129sv background also exhib-
ited a trend of Y maze impairment (One-way ANOVA
with post hoc test for linear trend, p = 0.017, Figure 8a).
But in the Bl6 background, tau-/- mice showed no differ-
ence in time spent in the novel arm compared to tau+/+
mice, indicating normal spatial memory (Figure 8a).
Thus, the Bl6/129sv background engenders greater vul-
nerability for cognitive degeneration caused by loss of
tau. Additionally, we found that tau-/- mice in the Bl6/
129sv background showed reduced distance of locomo-
tion (-30%, p = 0.002, Figure 8b), as well as reduced vel-
ocity (-36%, p < 0.001, Figure 8c) in the same Y maze
test, in accord with their observed motor deficits. Tau+/-
mice in the Bl6/129sv background also exhibited re-
duced distance of locomotion (-20%, p = 0.023, Figure 8b)
and a trend to slower velocity (One-way ANOVA with
post hoc test for linear trend, p = 0.003, Figure 8c). The
tau-/- mice in the Bl6 background ran a similar distance
compared to wild type mice (Figure 8b) and at a similar
speed (Figure 8c).Figure 8 Genetic background varies behaviors of mice at 12-months
novel arm during 5 mins recording time) of Y maze test. Two-way ANOVA:
genotype (p = 0.182) effects. Additional one-way ANOVA were performed t
b) Total distance of movement during the test. Two-way ANOVA: interaction
effect (p = 0.093). c) Velocity of movement during the test. Two-way ANOVA:
background effect (p = 0.157). *p < 0.05, **p < 0.01, versus age-matched wild t
group. Gender distribution is given in Additional file 6: Table S1. Data are meaWe considered whether dietary iron exposure, as a vari-
able between laboratories, could contribute to the toxic
accumulation of brain iron in the tau-/-, which we had re-
ported drives the motor and cognitive degenerative phe-
notypes [5]. The dietary iron content in the food in our
current study was markedly less than in our previous
study (78 ppm vs 590 ppm, Table 1), and compared with
the chow used by Morris et al. (78 ppm VS 220 ppm) [22].
Therefore, dietary iron exposure is unlikely to account for
the emergence of the phenotype.
Discussion
Evidence of PD-like contextual kinetic abnormalities in
tau-/- mice
The current study replicates the findings we published pre-
viously [5], and partially reconciles some of the findings
that were at variance with those of Morris and colleagues
[22]. In particular, we found that introduction of the
C57BL/6 strain into the original F1 FVB/129 background
[13] did not alter the Parkinson-like motor deficits that we
originally described [5]. We consistently observe a L-DOPA
responsive motor impairment in tau-/- mice independent of
the mouse body weight and genetic background, which we
interpret as a PD-like basal ganglia dysfunction phenotype.
This is further supported by our consistent observation of
TH-positive nigral neuron loss. Others have also reported
reduction in TH expression in the substantia nigra in tau-/-
mice [21], similar to our observations but inconsistent with
findings of Morris et al. [22]. Tau is implicated in PD by
being one of the major genetic risk factors [31-34], and by
interacting with α-synuclein [35-39]. There is a marked loss
of soluble tau in nigral tissue from PD cases [5]. Our
current data confirms that loss of normal soluble tau could
contribute to the motor deficits of PD.
We found in the current study that tau-/- mice on two
different genetic backgrounds showed significant reductionof age in Y maze test. a) Novel arm duration time (% time spent in
interaction (p = 0.04), but no genetic background (p = 0.664), or
o determine if genotype accounts for variance in Bl6/129sv group.
(p = 0.002) and genotype effect (p = 0.025), but no genetic background
interaction (p = 0.003) and genotype effect (p = 0.005), but no genetic
ype mice (Bonferroni post hoc test). n is indicated in the column of each
ns ± SEM.
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(Figure 4a), but increased time in movement and increased
(Bl6 only) distance of locomotion (Figure 4c,d). Their vel-
ocity remained unchanged (Figure 4b). We interpret this as
hyperkinesis with dyskinetic movements. The tau-/- mice
spent more time moving, but took smaller steps than nor-
mal mice. This is consistent with the animal being unable
to suppress movement, when there is lack of cognitive
intention (in contrast to the Y-maze task, vide infra), as
seen in PD. In addition, the increase in anxiety of the Open
Field Test could also be releasing more movements in the
tau-/- mice. This would also be a phenocopy of PD where
anxiety exacerbates motor symptoms and disability [40]. In
contrast, motor data from the Y-maze Test showed that
tau-/- mice in a Bl6/129sv background had a reduced total
distance of movement and velocity (Figure 8b,c). One hour
Open Field Test incorporates anxiety cues (prefrontal and
amygdala), whereas the 5 mins Y-maze Test involves more
frontal lobe and cognitive input, where the impaired mem-
ory of the tau-/- mice (Figure 8a) could limit the drive to
explore.Variance induced by genetic background
Our current findings also show that genetic strain may
contribute to the cognitive degeneration we reported
previously for tau-/- mice in a Bl6/129sv background [5],
as tau-/- mice in the Bl6 background did not express this
difference compared with wild type Bl6 mice in the Y-
maze test. Morris et al. additionally performed Morris
water maze and novel object recognition tests of tau-/-
mice in the Bl6 background, and found no cognitive
behavioral deficits [22]. However, Ma et al. reported that
tau-/- mice in the Bl6 background showed deficits in
Morris Water Maze test at 20-months of age [21], there-
fore it is possible that the velocity of cognitive degener-
ation in tau-/- mice is dependent on genetic background.Variance induced by environmental and dietary factors
The phenotype of tau-/- mice may also be sensitive to en-
vironmental and dietary factors. In our previous study, the
mice were housed in a conventional animal facility [5], in
contrast to the specific pathogen free (SPF) facility used
by Morris et al. [22]. In the current study, we re-derived
our colony in a SPF facility. Since the tau-/- mice in our
SPF facility showed similar deficits to the same strain in
our previous conventional facility, we conclude that the
presence of infectious pathogens in the facility is unlikely
to account for the phenotype we observe.
While we found no evidence that dietary iron levels
could account for the differences in phenotypes between
laboratories, we noticed that the mouse chow used by
Morris et al. contained 0.33% Omega-3 Fatty Acids,
compared to 0.07% in our previous mouse chow, and 0%
in our current chow. This raises the possibility that
Omega-3 Fatty Acids in the diet, which are known to
affect neurodegeneration [41,42], could offset the effects
of tau loss on age-related iron accumulation and subse-
quent toxicity. In fact, Ma et al. reported in their recent
publication that dietary supplementation with docosa-
hexaenoic acid (DHA) rescued both motor and cognitive
deficits they observed in tau-/- mice in Bl6 background
[21], suggesting that dietary differences may account for
some variance.
Possible variations induced by aging
One recent study using Bl6 background mice also re-
ported that they could not see differences in motor
phenotype or brain iron levels between tau-/- and WT
mice at 24 months of age [43], which is at apparent vari-
ance with findings of ours [5] or Ma et al. [21]. As we
previously suggested, the deficits in the tau-/- mice rep-
resent a form of accelerated aging where the mouse
manifests brain iron accumulation that is different from
age-matched controls from 7 to 12 months. Brain iron
levels in normal mice invariably rise with age [44-46],
and accompany cognitive and motor deficits, but the el-
evated iron levels and neurological deficits arise prema-
turely in the tau-/- mice. Indeed we previously did not
observe further behavioral decline post 12 months in
tau-/- mice [5]. Recent data from our group (Lei et al.
unpublished) indicate that by 24 months of age, the iron
levels in normal mice catch up to the elevated iron
levels in the tau-/- mice, which reach a ceiling value.
Taken together, these data characterize tau-/- mice as an
accelerated model for brain aging.
Conclusion
Recent large-scale phase III clinical trials of drugs directly
targeting the Aβ-related pathways involved in AD have
failed to benefit patients [47,48], and therapeutic ap-
proaches targeting tau are gaining attention because
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[11,15,49,50] and rescue the toxicity in mouse mutant
tau transgenic models [51-54]. Also, tau reduction is
protective against epilepsy [6,49,55]. Enthusiasm for tau
reduction as a therapeutic target is tempered by findings
that complete tau ablation causes iron-mediated neuro-
degeneration with aging, which is, however, ameliorated
by iron chelation [5] or antioxidant treatment [21]. In
this study, we re-validated that excess reduction of tau
protein leads to motor and cognitive consequences.
Others have shown that tau protein has synaptic func-
tions, and that tau ablation in aged mice or rats causes
impaired LTD [17] and LTP [16]. Furthermore, one re-
port warns that tau ablation worsens Aβ-induced cogni-
tive impairment at an older age [56]. Taken together, tau
may have important functions that sustain the longevity
of neurons. Therefore, rather than targeting tau expres-
sion directly, microtubule stabilizers that restore tau
function [57-59] or strategies that selectively lower iron




All mice were housed in a specific pathogen free (SPF)
facility according to standard animal care protocols and
fed standard laboratory chow (Code 102108, Barastoc,
Ridley AgriProducts) and tap water ad libitum. All ani-
mal procedures were approved by the Florey Institute
animal ethics committee (10-017-MHRI) and were per-
formed in accordance with the National Health and
Medical Research Council guidelines. Mice on a back-
ground of sv129 and C57Bl6 were originally obtained
from Dr. M. Vitek (Duke University) [13] and were in-
bred before we set up a breeding strategy to back cross
them for 10 generations onto a Bl6 background. Mice
with both genetic backgrounds were maintained homo-
zygously and mutants were backcrossed to the parental
inbred strain every 3 generations. Gender distributions
of the mice used in each experiment are given in
Additional file 6: Table S1.
L-DOPA treatment
Freshly dissolved L-DOPA in 0.9% NaCl, 0.5% Na-
carboxymethylcellulose, 0.5% benzyl alcohol, 0.4% Tween-
80, was administered by oral gavage useing of a blunted
oral-esophageal needle (18 g, cropping needle) at 10 mg kg−1
for one dose. The performance tests were carried out 1 hour
after the dose to allow maximal absorption.
Accelerated Rotarod test
Accelerated Rotarod test was performed as previously de-
scribed [5]. Briefly, mice were assessed on three occasions
(separated by 1 hour interval) using a Panlab Rotarodapparatus in an accelerating paradigm (4 to 40 rpm, max-
imum time of 3 min; speed increases every 8 s). The time
on the rod was recorded and the triplicates averaged for
analysis. Trials were excluded if the mouse jumped off the
rod.
Pole test
Pole test was performed as previously described [5].
Briefly, mice were placed vertically facing upward on the
top of a 30 cm vertical, 1cm diameter pole. The animals
were habituated to the pole on the day before the trial
by performing 5 consecutive mock trials. The trials on
the day of testing were recorded by digital video for tim-
ing analysis. The length of time each mouse took to turn
toward the ground (time to turn), and to reach the
ground (time to finish) was recorded for each trial. Each
mouse underwent five trials and the best trial was used
in analysis. Trials were excluded if the mouse jumped or
slid down the pole. The pole was cleaned between tests
using 70% ethanol.
Hindlimb Clasping test
Method for Hindlimb clasping test was adapted from
Lieu et al. [24]. Briefly, mice were suspended by the
base of the tail and their behaviors were recorded for
30 seconds. Three separate trials were taken over
course of test (1 hour apart). Hindlimb clasping was
rated from 0 to 3 based on severity: 0 = hindlimbs
splayed outward and away from the abdomen, 1 = one
hindlimb retracted inwards towards the abdomen for at
least 50% of the observation period, 2 = both hindlimbs
partially retracted inwards towards the abdomen for at
least 50% of the observation period, 3 = both hindlimbs
completely retracted inwards towards the abdomen for at
least 50% of the observation period. Scores of 0.5 were
used when appropriate. Hindlimb clasping severity scores
were calculated by averaging the three separate tests.
Open Field test
Open Field test was performed as previously described
[5]. Briefly, spontaneous motor activity of mice in an
enclosed arena (27.3 cm wide, 27.3 cm deep, 20.3 cm
high) was monitored using a 48 Channel IR Controller
photo-beam activity system (Med Associates Inc, USA)
and analyzed by Activity Monitor (Version 6.02, Med
Associates Inc, USA). The mouse was placed into the
chamber for one hour, and the data analyzed in 5 min
time bins. Movement parameters were calculated from
the interception of beams that provided XY coordinates.
Digigait test
The ambulatory gait analysis of mice was quantified using
the DigiGaitTM Imaging System (Mouse Specifics Inc.,
USA). A video camera mounted below a motorized
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mouse while walking. The paws of the mice were colored
with a red marker to improve contrast for automated ana-
lysis. Mice were placed on the treadmill and rapidly acceler-
ated to 15 cm/sec at which speed data was captured for
analysis. The total time of recording was approximately one
minute. Numerous postural and kinematic metrics of gait
dynamics were determined by Digigait 8 (Mouse Specifics
Inc., USA), representing the temporal record of paw place-
ment relative to the treadmill belt.
Y maze test
Y maze test was performed as previously described [5].
Briefly, a Y-shaped grey-painted timber with arms (29.5
cm long × 7.5 cm wide × 15.5 cm high) was used to as-
sess spatial recognition memory. All mice underwent a
2-part Y-maze test separated by a 1 h interval. The three
identical arms were randomly assigned start arm, novel
arm, and other arm. Visual cues were placed on the
walls of the maze. In the first part of the test (training),
the novel arm was occluded and mice were placed in the
start section of the maze and were allowed to freely
explore for 10 min. For the second part (test), access to
the novel arm was made available and mice were placed
back in the maze in the same starting arm, and allowed
to explore for 5 min. Behaviors were recorded on video
during a 5 min trial and the TopScan Realtime Option
Version 2.00 (Clever Sys Inc, USA) was used for analysis.
Data are expressed as the percentage of frequency and
duration for novel arm entries made during the 5-min
second trial. All testing performed during the light phase
of the circadian cycle.
Mouse brain preparation
Mouse brain samples were prepared as previously described
[5]. Briefly, mice were euthanized with an overdose of so-
dium pentobarbitone (Lethabard, 100mg/kg) and perfused
with ice-cold saline. The left brain hemisphere was fixed in
4% paraformaldehyde for 24 h, and then transferred to 30%
Sucrose + PBS (pH 7.4) and kept at 4°C overnight for tyro-
sine hydroxylase (TH) immunohistochemistry.
Stereological estimation of SN TH+ neurons
Tyrosine hydroxylase immunohistochemistry and SN
neuron counting were performed as previously described
[5]. Briefly, brains were frozen sectioned on a calibrated
Leica Cryostat in 30 μm sections. Sections (1:3 series)
were collected through the SN pars compacta (SNpc) (an-
teroposterior -2.92 to -3.64 mm from bregma). After brief
fixation (4% paraformaldehyde for 30 seconds), the sec-
tions were blocked in 3% normal goat serum (Millipore)
and incubated with primary anti-TH rabbit polyclonal
(1:3000, Millipore) overnight. The sections were then in-
cubated with goat anti-rabbit secondary HRP-conjugatedantibody for 3 hours (Millipore), followed by diaminoben-
zidine solution (1% in PBS + 1% CoCl2, 1% NiSO4) + 3%
hydrogen peroxide (1:3000). The numbers of neurons
within the SNpc were then estimated using a stereological
fractionator design. The counts were taken using an un-
biased counting frame of x = 35 μm, y = 45 μm (1575 μm2)
at regular intervals on a sampling grid of x = 140 μm,
y = 140 μm (19600 μm2), viewed with a 60 x 1.3 N.A. oil
objective (DMLB Leica Microscope) by the morphometry
and design-based stereology software package (Stereo
Investigator 10.04, Microbrightfield, Colchester, VT).
Metal measurement
Samples were prepared as previously described [5]. Briefly,
the mouse chow was re-suspended in 65% nitric acid
(Merck) overnight. The samples were then heated for 20
min at 90°C. The samples were diluted in double-distilled
water and assayed by an inductively coupled plasma mass
spectrometer (Agilent 7700). Each sample was measured
in triplicate and the concentrations determined from the
standard curve were normalized to weight.
Statistics
Statistical analysis was carried out in Prism 6 (GraphPad
Software Inc). All tests were two-tailed, with the level of
significance set at 0.05. Detailed tests used in each experi-
ment are described in Figure legends.
Additional files
Additional file 1: Figure S1. No correlation between weight and
Rotarod test performance in 12-month-old mice.
Additional file 2: Figure S2. No correlation between weight and Pole
test performance in 12-month-old mice.
Additional file 3: Figure S3. Temporal Open field profile.
Additional file 4: Figure S4. Analysis on 10 mins movement in Open
field test.
Additional file 5: Figure S5. Additional parameters analyzed by
Digigait apparatus.
Additional file 6: Table S1. Mouse number and gender used in each
experiment.
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